1279891-92-7

Basic information

• Product Name: N-[4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide
• Synonyms: N-[4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide
• CAS NO: 1279891-92-7
• Molecular Weight: 436.829
• Mol File: 1279891-92-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-[4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide(1279891-92-7)
• EPA Substance Registry System: N-[4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide(1279891-92-7)

Safety Data

• Hazardous Substances Data: 1279891-92-7(Hazardous Substances Data)

Upstream product

• 1429789-55-8 6-(4-amino-phenyl)-1H-pyrazolo[3,4-b]pyrazin-3-ylamine hydrochloride 
• 13656-57-0 5-chloro-2,4-difluorobenzene-1-sulfonyl chloride 

Relevant articles and documents

N-[ 4 - (1H-pyrazolo [3,4-b] pyrazin-6-yl)-phenyl]-sulfamide and their use as medicaments

The invention relates to N-[4-(1H-pyrazolo[3,4-b] pyrazine-6-yl)-phenyl]-sulfonamides of a formula I. In the formula I, Ar, R1, R2 and n have meanings as shown in the claims. The compounds of the formula I are compounds which are valuable, have pharmacological activity and can adjust the activity of protein kinase, particularly the activity of serum and glucocorticoid induced kinase (SGK), and more particularly the activity of serum and glucocorticoid induced kinase isoform (SGK-1, SGK1). The compounds are suitable for treating diseases with inappropriate activity of the SGK, such as degenerative joint diseases or inflammatory process such as osteoarthritis or rheumatism. The invention also relates to a method for preparing the compounds of the formula I, an application of the compounds serving as the medicines and medicine compositions containing the compounds.

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]- sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.